一项旨在研究1%塔匹那罗夫乳膏在3个月至<24个月特应性皮炎患儿中的安全性和有效性的研究 (Adoring)
一项随机、双盲、赋形剂对照(第1阶段)和开放标签(第2阶段)的3期研究,旨在调查1% Tapinarof乳膏在3个月至<24个月患有特应性皮炎的儿科参与者中的安全性和疗效
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
Alberta
-
Calgary、Alberta、加拿大、T2J 7E1
- Dermatology Research Institute
-
Red Deer、Alberta、加拿大、T4P 1K4
- CARe Clinic (Central Alberta Research Clinic)
-
-
British Columbia
-
Surrey、British Columbia、加拿大、V3R 6A7
- Dr. Chih-Ho Hong Medical Inc.
-
-
Manitoba
-
Winnipeg、Manitoba、加拿大、R3J 0S9
- Manitoba Allergy Research Inc.
-
-
Nova Scotia
-
Halifax、Nova Scotia、加拿大、B3K 5R3
- Maritime Dermatology
-
-
Ontario
-
Burlington、Ontario、加拿大、L7L 6W6
- Halton Pediatric Allergy
-
Hamilton、Ontario、加拿大、L8S 1G5
- Triple A Lab Inc.
-
Niagara Falls、Ontario、加拿大、L2H 1C4
- Allergy Research Canada Inc.
-
-
Saskatchewan
-
Regina、Saskatchewan、加拿大、S4V 1R9
- Dr. Rachel Asiniwasis Medical Professional Corporation
-
Saskatoon、Saskatchewan、加拿大、S7K 2C1
- Skinsense Medical Research
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35209
- AllerVie Clinical Research
-
-
Arkansas
-
Bryant、Arkansas、美国、72022
- Dermatology Trial Associates
-
-
California
-
Los Angeles、California、美国、90045
- Dermatology Research Associates
-
Sacramento、California、美国、95815
- Integrative Skin Science and Research
-
San Diego、California、美国、92123
- Allergy and Asthma Medical Group and Research Center
-
Thousand Oaks、California、美国、91320
- Clinical Trials Research Institute
-
-
Colorado
-
Castle Rock、Colorado、美国、80109
- Clarity Dermatology
-
-
Florida
-
Boca Raton、Florida、美国、33486
- Skin Care Research, LLC.
-
Jacksonville、Florida、美国、32256
- APEX Clinical Trials
-
Wellington、Florida、美国、33449
- TruDerm Research
-
-
Georgia
-
Cumming、Georgia、美国、30040
- Cleaver Medical Group Dermatology, Inc
-
-
Idaho
-
Meridian、Idaho、美国、83646
- Ada West Research
-
-
Illinois
-
Skokie、Illinois、美国、60077
- Endeavor Health Clinical Trials Center
-
-
Indiana
-
Indianapolis、Indiana、美国、46250
- Dawes Fretzin Clinical Research Group, LLC
-
Plainfield、Indiana、美国、46168
- The Indiana Clinical Trials Center, PC
-
-
Kentucky
-
Bowling Green、Kentucky、美国、42104
- Equity Medical, LLC
-
-
Maryland
-
Rockville、Maryland、美国、20850
- Lawrence J Green, MD LLC
-
-
Michigan
-
Auburn Hills、Michigan、美国、48326
- Oakland Hills Dermatology
-
-
Minnesota
-
New Brighton、Minnesota、美国、55112
- Minnesota Clinical Study Center
-
-
Mississippi
-
Ridgeland、Mississippi、美国、39157
- SKY Integrative Medical Center
-
-
Missouri
-
Saint Joseph、Missouri、美国、64506
- MediSearch Clinical Trials
-
-
Nevada
-
Reno、Nevada、美国、89509
- Skin Cancer and Dermatology Institute
-
-
New York
-
Kew Gardens、New York、美国、11415
- Forest Hills Dermatology Group
-
New York、New York、美国、10012
- Bobby Buka MD, PC
-
The Bronx、New York、美国、10455
- Equity Medical, LLC
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27516
- The University of North Carolina Dermatology and Skin Cancer Center
-
-
Ohio
-
Fairborn、Ohio、美国、45324
- Dermatologists of Central States, LLC
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73120
- Allergy Asthma and Clinical Research Center
-
-
Oregon
-
Portland、Oregon、美国、97210
- Oregon Dermatology and Research Center
-
Portland、Oregon、美国、97239
- Oregon Health & Science University
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- Medical University of South Carolina
-
North Charleston、South Carolina、美国、29420
- National Allergy and Asthma Research, LLC.
-
-
Texas
-
Bellaire、Texas、美国、77401
- The University of Texas Health Science Center at Houston
-
Dallas、Texas、美国、75230
- Dermatology Treatment and Research Center
-
Southlake、Texas、美国、76092
- Stryde Research - Epiphany Dermatology
-
-
Washington
-
Spokane、Washington、美国、99202
- Dermatology Specialists of Spokane
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to <24 months of age at the Screening visit.
- Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
- Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
- Legal guardian or primary caregiver is able and willing to adhere to protocol requirements
Exclusion Criteria:
- Significant neurological disorder or history of seizure
- Know clinically significant cardiac rhythm or cardiac disorder
- History of sudden infant death in a sibling
- Clinically significant chromosome abnormality
- History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
- Diseases that could cause pruritic and/or sleep disruption
- Immunocompromised
- Current chronic or acute infection requiring treatment
- Use of prohibited medication(s) or procedure(s)
- Use of prohibited medications by breastfeeding mother if breastfeeding participant
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Tapinarof cream
Tapinarof cream, 1%, applied topically once daily |
Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.
其他名称:
|
|
安慰剂比较:Vehicle cream
Vehicle cream is applied topically once daily for up to 8-weeks. |
Applied topically once daily to lesions on participant's skin during the Double-Blind period. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8
大体时间:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label Period
大体时间:Baseline to the end of the Open-Label Period, up to 56 weeks.
|
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint.. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. |
Baseline to the end of the Open-Label Period, up to 56 weeks.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of participants with ≥ 75% improvement in Eczema Area and Severity Index (EASI) Score from Baseline to Week 8.
大体时间:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the %BSA affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. A higher EASI score represents more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Mean change in percentage of total body surface area (%BSA) affected from Baseline to Week 8
大体时间:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
Assessment of %BSA is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% [10 handprints], upper extremities = 20% [20 handprints], trunk (including axillae and groin) = 30% [30 handprints], lower extremities, including buttocks, = 40% [40 handprints]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Percentage of participants with ≥ 90% improvement in Eczema Area and Severity Index (EASI) score from Baseline to Week 8
大体时间:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
Severity Index (EASI) score from Baseline to Week 8 Description: The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
大体时间:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
大体时间:Baseline to the end of the Open-Label Period, up to 56 weeks
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to the end of the Open-Label Period, up to 56 weeks
|
|
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
大体时间:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
|
|
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
大体时间:Baseline to the end of the Open-Label Period, up to 56 weeks.
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to the end of the Open-Label Period, up to 56 weeks.
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
大体时间:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
大体时间:Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
大体时间:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
大体时间:Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
合作者和调查者
调查人员
- 研究主任:Clinical Lead Late-Stage Clinical Development、Organon and Co
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.